What are the cut-off values for starting In-Patient Department (IPD) and Out-Patient Department (OPD) treatment and what are the typical prescriptions for patients with abnormal lab results, such as acute kidney injury, severe anemia, and hyperglycemia?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: November 24, 2025View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

Cut-off Values and Treatment Protocols for IPD vs OPD Management in Indian Clinical Practice

Acute Kidney Injury (AKI)

Admit to IPD (In-Patient Department) if AKI Stage 2 or higher, or Stage 1 with complications; manage Stage 1 without complications in OPD with close monitoring.

Cut-off Values for IPD Admission 1:

  • AKI Stage 2: Serum creatinine 2.0-2.9 times baseline OR urine output <0.5 ml/kg/h for ≥12 hours 1
  • AKI Stage 3: Serum creatinine ≥3.0 times baseline OR creatinine ≥4.0 mg/dl (354 μmol/l) OR urine output <0.3 ml/kg/h for ≥24 hours OR anuria for ≥12 hours OR initiation of renal replacement therapy 1
  • AKI Stage 1 with complications: Hemodynamic instability, oliguria not responding to fluids, hyperkalemia, severe acidosis, or uremic symptoms 1

Cut-off Values for OPD Management 1:

  • AKI Stage 1: Creatinine increase ≥0.3 mg/dl (26.5 μmol/l) within 48h OR 1.5-1.9 times baseline OR urine output <0.5 ml/kg/h for 6-12h, WITHOUT complications 1
  • Patient hemodynamically stable, able to maintain oral intake, no electrolyte abnormalities 1

IPD Prescription for AKI Stage 2-3:

Monitoring:

  • Serum creatinine, urea, electrolytes (Na, K, Cl, HCO3) daily 1
  • Urine output hourly initially, then 4-hourly 1
  • Daily weight, fluid balance chart 1

Fluid Management:

  • Isotonic saline or balanced crystalloid (Ringer's lactate/Plasma-Lyte) for volume expansion 1
  • Avoid hydroxyethyl starch solutions 1
  • Target euvolemia; restrict fluids if oliguric 1

Medications:

  • Hold nephrotoxic drugs (NSAIDs, aminoglycosides, ACE inhibitors/ARBs if hemodynamically unstable) 1, 2
  • Adjust drug doses for GFR <60 ml/min/1.73 m² 2
  • Norepinephrine as first-line vasopressor if shock (avoid dopamine) 1

Nutrition 1:

  • Enteral route preferred 1
  • Energy: 25-30 kcal/kg/day 1
  • Protein: Start 1.0 g/kg/day, increase to 1.3 g/kg/day if tolerated and not on dialysis 1
  • If on CRRT/SLED: Protein 1.5-1.7 g/kg/day 1

Glycemic Control:

  • Target blood glucose 110-149 mg/dL 1
  • Avoid rapid correction in poorly controlled diabetics 1

Indications for Dialysis:

  • Refractory hyperkalemia (K >6.5 mEq/L despite medical management) 1
  • Severe metabolic acidosis (pH <7.15) 1
  • Volume overload unresponsive to diuretics 1
  • Uremic complications (pericarditis, encephalopathy, bleeding) 1
  • Creatinine ≥4.0 mg/dl with acute rise 1

OPD Prescription for AKI Stage 1:

Monitoring:

  • Serum creatinine, urea, electrolytes every 2-3 days initially 1
  • Daily weight and fluid intake/output diary 1

Fluid Management:

  • Oral hydration 2-3 liters/day unless contraindicated 1
  • Avoid dehydration and volume depletion 1

Medications:

  • Discontinue or adjust nephrotoxic drugs 2
  • Review and adjust doses of renally excreted medications 2

Nutrition:

  • Protein 0.8-1.0 g/kg/day 1
  • Adequate caloric intake 25-30 kcal/kg/day 1

Follow-up:

  • Review in 3-5 days or earlier if worsening symptoms 1
  • Escalate to IPD if progression to Stage 2 or complications develop 1

Severe Anemia

Admit to IPD if hemoglobin <7 g/dL, or <10 g/dL with hemodynamic instability, active bleeding, or cardiac symptoms; manage stable patients with Hb 7-10 g/dL in OPD.

Cut-off Values for IPD Admission:

  • Hemoglobin <7 g/dL regardless of symptoms 3, 4
  • Hemoglobin <10 g/dL with: hemodynamic instability, active bleeding, angina, heart failure, or severe dyspnea 4, 5
  • Hemoglobin <10.5 g/dL in critically ill or post-cardiac surgery patients 4, 5
  • Symptomatic anemia requiring urgent transfusion 3

Cut-off Values for OPD Management:

  • Hemoglobin 7-10 g/dL in stable, asymptomatic patients 3
  • No active bleeding or hemodynamic compromise 4
  • Able to tolerate oral iron therapy 3

IPD Prescription for Severe Anemia (Hb <7 g/dL or symptomatic):

Immediate Management:

  • Type and cross-match blood 3
  • Packed red blood cell transfusion: 1 unit raises Hb by ~1 g/dL 3
  • Target Hb >7 g/dL in stable patients, >10 g/dL if cardiac disease or ongoing bleeding 4, 5

Investigations:

  • Complete blood count with peripheral smear 3
  • Reticulocyte count, serum iron, TIBC, ferritin, vitamin B12, folate 3
  • Stool for occult blood, upper GI endoscopy if indicated 3
  • Renal function tests (anemia common in AKI/CKD) 6, 7, 4

Iron Therapy 3:

  • IV iron preferred if Hb <10 g/dL: Iron sucrose 200 mg IV 3 times/week OR Ferric carboxymaltose 500-1000 mg IV once weekly 3
  • Target ferritin >100 ng/ml, transferrin saturation >20% 3

Erythropoiesis-Stimulating Agents (if CKD-related) 3:

  • Erythropoietin 50-100 units/kg SC 3 times/week OR Darbepoetin 0.45 mcg/kg SC weekly 3
  • Target Hb 11-12 g/dL (avoid normalization) 3

Monitoring:

  • Hemoglobin every 2-3 days until stable 3
  • Daily vitals, urine output 4

OPD Prescription for Moderate Anemia (Hb 7-10 g/dL, stable):

Oral Iron Therapy 3:

  • Ferrous sulfate 325 mg (65 mg elemental iron) TID on empty stomach 3
  • OR Ferrous fumarate 200 mg (66 mg elemental iron) TID 3
  • Add vitamin C 250 mg to enhance absorption 3

Investigations:

  • Same as IPD workup to identify cause 3

Monitoring:

  • Hemoglobin, reticulocyte count every 2-4 weeks 3
  • Ferritin, transferrin saturation at 3 months 3

Follow-up:

  • Review in 2 weeks initially, then monthly 3
  • Escalate to IPD if Hb drops <7 g/dL or develops symptoms 4

Hyperglycemia

Admit to IPD if blood glucose >400 mg/dL with ketosis/acidosis (DKA), hyperosmolar state (HHS), or glucose >300 mg/dL with severe symptoms; manage uncomplicated hyperglycemia (glucose 200-300 mg/dL) in OPD.

Cut-off Values for IPD Admission:

  • Diabetic Ketoacidosis (DKA): Glucose >250 mg/dL + pH <7.3 + bicarbonate <18 mEq/L + ketonemia/ketonuria 1
  • Hyperosmolar Hyperglycemic State (HHS): Glucose >600 mg/dL + serum osmolality >320 mOsm/kg + altered mental status 1
  • Blood glucose >400 mg/dL with dehydration or inability to maintain oral intake 1
  • Blood glucose >300 mg/dL with severe symptoms (polyuria, polydipsia, weakness, altered sensorium) 1
  • New-onset diabetes with severe hyperglycemia 1

Cut-off Values for OPD Management:

  • Blood glucose 200-300 mg/dL without ketosis, stable vital signs, able to eat/drink 1
  • Known diabetic with poor control but no acute complications 1
  • HbA1c >9% requiring intensification of therapy 1

IPD Prescription for DKA/Severe Hyperglycemia:

Immediate Management:

  • IV access, continuous cardiac monitoring 1
  • Fluid resuscitation: Normal saline 1 liter over first hour, then 250-500 ml/hr based on hydration status 1

Insulin Therapy:

  • IV regular insulin infusion: 0.1 units/kg/hr (typically 5-10 units/hr) 1
  • Once glucose <250 mg/dL, switch to dextrose-containing fluids and reduce insulin to 0.05 units/kg/hr 1
  • Continue IV insulin until ketosis resolves (pH >7.3, bicarbonate >18 mEq/L) 1

Electrolyte Management 1:

  • Potassium: Add 20-40 mEq/L to IV fluids if K <5.3 mEq/L (hold insulin if K <3.3 mEq/L) 1
  • Monitor K every 2-4 hours 1
  • Phosphate replacement if <1.0 mg/dL 1

Monitoring:

  • Blood glucose hourly initially 1
  • Electrolytes, venous pH, bicarbonate every 2-4 hours 1
  • Target glucose 110-149 mg/dL in critically ill (avoid tight control <110 mg/dL) 1

Transition to Subcutaneous Insulin:

  • Once eating, give SC basal-bolus insulin 2 hours before stopping IV insulin 1
  • Total daily dose: 0.5-0.8 units/kg/day (50% basal, 50% bolus divided before meals) 1

OPD Prescription for Uncomplicated Hyperglycemia (200-300 mg/dL):

Oral Antidiabetic Agents:

  • Metformin: Start 500 mg BD, increase to 1000 mg BD after 1 week (max 2000 mg/day) 1
  • Contraindicated if eGFR <30 ml/min/1.73 m² 1

Add-on Therapy if inadequate control:

  • Sulfonylurea: Glimepiride 1-2 mg OD OR Gliclazide MR 30-60 mg OD 1
  • DPP-4 inhibitor: Sitagliptin 100 mg OD OR Vildagliptin 50 mg BD 1
  • SGLT2 inhibitor (if eGFR >30): Dapagliflozin 10 mg OD OR Empagliflozin 10 mg OD 1

Insulin (if glucose persistently >300 mg/dL):

  • Basal insulin: Glargine or Detemir 10 units SC at bedtime, titrate by 2 units every 3 days to achieve fasting glucose 80-130 mg/dL 1

Monitoring:

  • Self-monitoring blood glucose: Fasting and 2-hour post-prandial daily initially 1
  • HbA1c every 3 months 1

Lifestyle Modifications:

  • Medical nutrition therapy: 1500-1800 kcal/day, carbohydrate 45-60% of total calories 1
  • Exercise: 150 minutes/week moderate-intensity aerobic activity 1

Follow-up:

  • Review in 1-2 weeks initially, then monthly until stable 1
  • Escalate to IPD if glucose >400 mg/dL or develops DKA/HHS 1

Common Pitfalls to Avoid

AKI Management:

  • Do not use dopamine for renal protection (increases complications vs. norepinephrine) 1
  • Avoid hydroxyethyl starch solutions (increase AKI risk) 1
  • Do not withhold protein to delay dialysis (increases catabolism) 1
  • Monitor potassium closely when using ACE inhibitors/ARBs (risk of hyperkalemia and AKI) 1

Anemia Management:

  • Do not normalize hemoglobin with ESAs (target 11-12 g/dL, not >13 g/dL) 3
  • IV iron more effective than oral in hospitalized patients 3
  • Anemia with Hb <10.5 g/dL increases AKI risk in critically ill patients 4, 5

Hyperglycemia Management:

  • Avoid rapid correction in poorly controlled diabetics (may worsen outcomes) 1
  • Do not use tight glucose control <110 mg/dL in critically ill (increases hypoglycemia risk) 1
  • SGLT2 inhibitors increase risk of euglycemic DKA (monitor ketones) 1
  • Metformin contraindicated in AKI or eGFR <30 ml/min/1.73 m² 1, 2

References

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.